12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25–50 mg/day) versus escitalopram (10–20 mg/day) in out-patients with severe generalized anxiety disorder. Stein, D J, Khoo, J P, Ahokas, A, Jarema, M, Van Ameringen, M, Vavrusova, L, Hӧschl, C, Bauer, M, Bitter, I, Mosolov, S N, Olivier, V, Matharan, S, Picarel-Blanchot, F, & de Bodinat, C European Neuropsychopharmacology, 28(8):970–979, 2018.
12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25–50 mg/day) versus escitalopram (10–20 mg/day) in out-patients with severe generalized anxiety disorder [link]Paper  doi  bibtex   
@article{Stein2018b,
	title = {12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25–50 mg/day) versus escitalopram (10–20 mg/day) in out-patients with severe generalized anxiety disorder},
	volume = {28},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85049594777&doi=10.1016%2Fj.euroneuro.2018.05.006&partnerID=40&md5=5f86802377e06b860107263afc757430},
	doi = {10.1016/j.euroneuro.2018.05.006},
	number = {8},
	journal = {European Neuropsychopharmacology},
	author = {Stein, D J and Khoo, J P and Ahokas, A and Jarema, M and Van Ameringen, M and Vavrusova, L and Hӧschl, C and Bauer, M and Bitter, I and Mosolov, S N and Olivier, V and Matharan, S and Picarel-Blanchot, F and de Bodinat, C},
	year = {2018},
	pages = {970--979},
}

Downloads: 0